NCT00729053

Study of IMO-2055 in Metastatic or Locally Recurrent Clear Cell Renal Carcinoma

A Phase 2, Multi-Center, Randomized, Open-Label Study of Two Dose Levels of IMOxine® (IMO-2055 for Injection) in Patients With Metastatic or Locally Recurrent Clear Cell Renal Carcinoma

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 92 (actual)
• Sponsor: Idera Pharmaceuticals, Inc. · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

* Multi-Center * Randomized * Open-Label Study of single agent IMO-2055 * Patients who have Metastatic or Locally Recurrent Clear Cell Renal Carcinoma (RCC)

Detailed description

This is a study of 2 dose levels (0.16 or 0.64 mg/kg) of IMO-2055 administered by weekly subcutaneous (SC) injections in two patient populations, treatment naïve or previously treated patients. Each dose group (treatment naive or previously treated) will be randomized to receive one of the 2 doses being studied.

Conditions

• Renal Cell Carcinoma

Interventions

Type	Name	Description
DRUG	IMO-2055	immunostimulatory oligonucleotide

Timeline

• Start date: 2004-06-01
• Primary completion: 2008-04-01
• Completion: 2008-11-01
• First posted: 2008-08-06
• Last updated: 2018-06-12
• Results posted: 2018-06-12

Locations

1 site across 1 country: United States